Prevention of sepsis in asplenic patients;Prevención de la sepsis en pacientes esplenectomizados

Cirugia Espanola

Volumn 81, Issue 5, 2007, Pages 247-251

  Lamsfus Prieto, José Ángel ^a   Membrilla Fernández, Estela ^a,b   Garcés Jarque, Josep Maria ^a  

^a HOSPITAL DEL MAR   (Spain)

^b NONE   (Spain)

Author keywords

Antibiotic prophylaxis; Meningococcal vaccination; Pneumococcal vaccination; Prophylaxis in asplenic patients; Splenectomy; Vaccination prophylaxis

Indexed keywords

EID: 34250381004     PISSN: 0009739X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-739X(07)71313-1     Document Type: Review

References (20)

1. Sumaraju V, Smith LG, Smith SM. Infectious complications in asplenic host. Infec Dis Clin North Am. 2001; 15:551-65.
2. Lutwick LI. Infections in asplenic patient. En: Mandell GL, Bennet JE, Dolin R, editores. Principles and Practice of Infectious Diseases. 5.a ed. Philadelphia: Elsevier; 2000. p. 3169-76.
3. Castagnola E, Fioredda F. Prevention of life-threatering infections due to encapsulate bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur J Haematol. 2003;71:319-26.
4. Kyaw MH, Holmes EM, Toolis F, Wayne B, Chalmers J, Jones IG, et al. Evaluation of severe infection and survival after splenectomy. Am J Med. 2006;119:e1-7.
5. Waghorm DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol. 200;54:214-8.
6. Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect. 2001;7:657-60.
7. Shatz DV, Schinsky MF, Pais LB, Romero-Steiner A, Kirton OC, Carlone GM. Imnune responses of splenectomized trauma patient to 23-valent pneumococal polysaccharide vaccine at 1 versus 7 days after splenectomy. J Trauma. 1998;44:760-6.
8. Shatz DV, Romero-Steiner S, Elie CM, Holder PF, Carlone GM. Antibody responses in postsplenectomy trauma patients reciving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively. J Trauma. 2002;53:1037-42.
9. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analisis of the prospective trials. BMC Family Practice. 2000-1;1. Disponible en: http://biomedcentral.com/1471-2296/1/ 1.
10. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. Guidelines for the prevention and treatment of infection in patients with an absente or dysfunctional spleen. BMJ. 1996;312:430-4.
11. The Advisory Committee on Immunization Practices. Prevention of pneumococcal disease. MMWR RR. 1997;46(RR-8).
12. Campins-Martí M, Moraga-Llop F. Calendarios vacunales en situaciones especiales. En: 2003 Vacunas. Barcelona: Prous Science; 2003. p. 101-16.
13. Quimioprofilaxis. Sepsis en pacientes esplenectomizados. En: Mensa J, Gatell JM, Jiménez de Anta MT, Prats G, Domínguez-Gil A. Guía Antimicrobiana 2004. 14.a ed. Barcelona: 2004. p. 717-8.
14. Recommenddations of the Advisory Committee on Immunizacion Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR RR. 1993;42(RR-4).
15. Committee on Infectious Diseases. American Academy of Pediatrics. Policy Statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-6.
16. Davies JM, Barnes R, Milligan D; for the Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med JRCPL. 2002;2:440-3.
17. Pasternack MS. Clinical features, management, and prevention of sepsis in the splenectomized patient, last change July 2002. Upto-Date on line 12.1.
18. Finn A, Booy R, Moxon R, Sharland M, Heath P. Should the new pneumococcal vaccine be used in high-risk children? Arch Dis Child. 2002;87:18-21.
19. The Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule by Age Group and Medical conditions United States, 2003-2004. Department of Health and Human Services. Center for Disease Control and Prevention. Disponible en: http://www.cdc.gov/nip/recs/ adult-schedule.htm#print. Acceso: 30 diciembre 2006.
20. Larrauri A, Cano A, De Mateo S. Enfermedad meningocócica en España. Temporada 2002-2003. Impacto de la vacuna conjugada en las tres tempordas posteriores a su introducción en España. Boletín Epidemiológico Semanal. 2004; 12:13-6.